Online Situation Room: Improving the Ability to Diagnose and Treat Atopic Dermatitis in Clinical Practice A part of the THRIVE – Atopic Dermatitis Initiative
Peter Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Medical Dermatology Associates of Chicago
Jonathan Spergel, MD, PhD
Professor of Pediatrics
Chief, Allergy Section
Stuart E. Starr Endowed Chair of Pediatrics
Director, World Allergy Organization Center of Excellence
Director of Center for Pediatric Eosinophilic Disease
Director, FARE Center of Excellence at The Children’s Hospital of Philadelphia
The Children’s Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
This “situation room” activity allows learners to practice making clinical decisions in the management of patients with moderate-to-severe atopic dermatitis. Learners will view simulated 3D interactions between patients and their physicians and use information from the patients’ electronic charts to decide the next best course of action. Topics covered in this activity include assessment of disease severity and quality of life, intensification of treatment, and recognizing adverse events.
This activity is intended for dermatologists, allergists/immunologists, and primary healthcare professionals (physicians, nurse practitioners, and physician assistants) involved in the management of patients with AD.
Upon the completion of this program, attendees should be able to:
- Describe the role of Type 2 cytokines in the pathophysiology of AD and other overlapping Type 2 diseases
- Incorporate AD diagnostic and assessment tools as well as consideration of patient-specific factors in clinical evaluations of patients with AD
- Discuss the safety and efficacy of existing and emerging AD treatments based on current research and clinical trial data
- Review the comorbid conditions associated with AD, such as asthma and allergic conjunctivitis, and how to manage them in clinical practice
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with atopic dermatitis.
Credits: 1.0 ANCC Contact Hours
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
|Dr. Lio has served on the advisory board for the National Eczema Association, Modernizing Medicine, Johnson & Johnson, DermTap Inc., IntraDerm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Syncere Skin Systems, DermVeda, GPower Inc., UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Verrica Pharmaceuticals Inc., Arbonne, Yobee Care Inc., and Bodewell. Dr. Lio is a stockholder in Modernizing Medicine, LearnHealth/LearnSkin, and Medable. He has been a speaker for Pierre Fabre Dermatologie, Regeneron, Pfizer, and La Roche-Posay. He has been an investigator for La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis), AOBiome LLC, Regeneron, AbbVie, and National Eczema Association. He has been a consultant for Exeltis, Therplex, Odeza LLC, L’Oreal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Eli Lilly and Co., Unilever, Dermira, TopMD, Amyris Inc., Leo Pharma, and Burt’s Bees.
Dr. Spergel is a consultant for Regeneron- Sanofi, Novartis, DBV Technology, and Kaleo. Dr. Spergel has completed contracted research for Regeneron-Sanofi, and Novartis, and has received royalty from Uptodate.
|CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Diana Tommasi, Director of Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this live activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the activity.
- Submit the evaluation form to Med Learning Group.
You will receive your certificate upon completion as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
RELEASE DATE: November 4, 2020
EXPIRATION DATE: November 4, 2021
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Med learning group will be glad to assist you with any special needs. Please contact Med Learning Group at any time at email@example.com.
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.